| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b74695f4c6259a8598b722c1ef6eefa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-01098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2005-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e77c4d53ee51751d70c2f5c100d1c1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58be8a922077df4a9c3169e68ebaef37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49da690562650db844efb97061469573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a605aa85212bea035aa3cb6b6e973e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab3655d2601c21af1efe6b5bf641178f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06435ffe5e431c81fff08ed408d1490d |
| publicationDate |
2007-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2275400-A1 |
| titleOfInvention |
USE OF AGONIST COMPOUNDS OF THE TACTICAL ACTIVITY TUBULINA DEACETILASA PROTEIN HDAC6 IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND ITS APPLICATIONS IN THE TREATMENT OF VIRAL INFECTIONS. |
| abstract |
Use of agonist compounds of the activitynHDAC6 protein tubulin deacetylase in the preparation ofnpharmaceutical compositions, said pharmaceutical compositions andnits applications in the treatment of viral infections.n n n The present invention is based on the fact thatnthe balance of acetylation / deacetylation of microtubulesnIt is key to modulate the entry of spherogenic viruses into cellsneukaryotes, preferably virus entrynHIV-1 in T cells, and that is regulated by thenHDAC6 protein, which allows defining new approachesnTherapeutics for prophylaxis and treatment of infectionsnviral. These therapeutic approaches are based on the use ofncompounds activating the activity of said HDAC6 protein and ofnthe pharmaceutical compositions containing them in methods ofnTreatment of such viral infections. |
| priorityDate |
2005-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |